• 1
    Chan PK. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002; 34(Suppl. 2):S58S64.
  • 2
    Peiris JS, Yu WC, Leung CW et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004; 363:617619.
  • 3
    Lee N, Hui DS, Wu A, Chan P et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:19861994.
  • 4
    WHO Writing Committee. Clinical aspects of pandemic influenza A (H1N1) 2009. N Engl J Med 2010; 362:17081719.
  • 5
    de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:12031207.
  • 6
    Lee N, Chan PK, Wong CK et al. Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia. Antivir Ther 2011; 16:237247.
  • 7
    To KK, Hung IF, Li IW et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850859.
  • 8
    Lee N, Choi KW, Chan PK et al. Outcomes of adults hospitalized with severe influenza. Thorax 2010; 65:510515.
  • 9
    Wong CK, Lam CW, Wu AK et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95103.
  • 10
    Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS ONE 2012; 7:e47926.
  • 11
    Lee N, Hui DS. Dexamethasone in community-acquired pneumonia. Lancet 2011; 378:979980.
  • 12
    Lee N, Chan PK, Hui DS et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200:492500.
  • 13
    Kudo K, Takasaki J, Manabe T et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS ONE 2012; 7:e32280.
  • 14
    Martin-Loeches I, Lisboa T, Rhodes A et al. ESICM H1N1 Registry Contributors. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med 2011; 37:272283.
  • 15
    Brun-Buisson C, Richard JC, Mercat A et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011; 183:12001206.
  • 16
    Kim SH, Hong SB, Yun SC et al. Korean Society of Critical Care Medicine H1N1 Collaborative. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med 2011; 183:12071214.
  • 17
    Han K, Ma H, An X et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1 infection. Clin Infect Dis 2011; 53:326333.
  • 18
    Diaz E, Martin-Loeches I, Canadell L et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect 2012; 64:311318.
  • 19
    Linko R, Pettilä V, Ruokonen E et al. Corticosteroid therapy in intensive care unit patients with PCR-confirmed influenza A(H1N1) infection in Finland. Acta Anaesthesiol Scand 2011; 55:971979.
  • 20
    Tang NL, Chan PK, Wong CK et al. Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 2005; 51:23332340.
  • 21
    Tse GM, To KF, Chan PK et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004; 57:260265.
  • 22
    Lee N, Chan AK, Hui DS et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304309.
  • 23
    Chen RC, Tang XP, Tan SY et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 2006; 129:14411452.
  • 24
    Wang H, Ding Y, Li X et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003; 349:507508.
  • 25
    Yap FH, Gomersall CD, Fung KS et al. Increase in methicillin-resistant Staphylococcus aureus acquisition rate and change in pathogen pattern associated with an outbreak of severe acute respiratory syndrome. Clin Infect Dis 2004; 39:511516.
  • 26
    Griffith JF, Antonio GE, Kumta SM et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235:168175.
  • 27
    Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004; 59:602608.
  • 28
    Lat A, Bhadelia N, Miko B et al. Invasive aspergillosis after pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16:971973.
  • 29
    Buckingham SC, Jafri HS, Bush AJ et al. A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J Infect Dis 2002; 185:12221228.
  • 30
    Gustafson LM, Proud D, Hendley JO et al. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996; 97:10091014.
  • 31
    Puhakka T, Mäkelä MJ, Malmström K et al. The common cold: effects of intranasal fluticasone propionate treatment. J Allergy Clin Immunol 1998; 101:726731.
  • 32
    Domachowske JB, Bonville CA, Ali-Ahmad D et al. Glucocorticoid administration accelerates mortality of pneumovirus infected mice. J Infect Dis 2001; 184:15181523.
  • 33
    Luke T, Kilbane E, Jackson J, Hoffman S. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145:599609.
  • 34
    Soo YO, Cheng Y, Wong R et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676678.
  • 35
    Cheng Y, Wong R, Soo YO et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:4446.
  • 36
    Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 2007; 357:14501451.
  • 37
    Hung IF, To KK, Lee CK et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:510519.
  • 38
    Hung IF, To KK, Lee CK et al. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest 2013; 144:464473.
  • 39
    Geiler J, Michaelis M, Naczk P et al. N-acetyl-l-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus. Biochem Pharmacol 2010; 79:413420.
  • 40
    Lai KY, Ng WY, Osburga Chan PK et al. High-dose N-acetylcysteine therapy for novel H1N1 influenza pneumonia. Ann Intern Med 2010; 152:687688.
  • 41
    Garozzo A, Tempera G, Ungheri D et al. N-acetylcysteine synergizes with oseltamivir in protecting mice from lethal influenza infection. Int J Immunopathol Pharmacol 2007; 20:349354.
  • 42
    Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 2011; 82:548555.
  • 43
    Takeda S, Munakata R, Abe S et al. Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion. Intens Care Med 2010; 36:906907.
  • 44
    Patel P, Nadwani V, Vanchiere J et al. Use of therapeutic plasma exchange as a rescue therapy in 2009 pH1N1 influenza-An associated respiratory failure and hemodynamic shock. Pediatr Crit Care Med 2011; 12:e87e89.
  • 45
    Hong DK, Tremoulet AH, Burns JC et al. Cross-reactive neutralizing antibody against pandemic 2009 H1N1 influenza A virus in intravenous immunoglobulin preparations. Pediatr Infect Dis J 2011; 30:6769.
  • 46
    Chong JL, Sapari S, Kuan YC. A case of acute respiratory distress syndrome associated with novel H1N1 treated with intravenous immunoglobulin G. J Microbiol Immunol Infect 2011; 44:319322.
  • 47
    Kubota-Koketsu R, Yunoki M, Okuno Y, Ikuta K. Significant neutralizing activities against H2N2 influenza A viruses in human intravenous immunoglobulin lots manufactured from 1993 to 2010. Biologics 2012; 6:245247.
  • 48
    Lew TW, Kwek TK, Tai D et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003; 290:374380.
  • 49
    Chong PY, Chui P, Ling AE et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004; 128:195204.
  • 50
    Umapathi T, Kor AC, Venketasubramanian N et al. Large artery ischemic stroke in severe acute respiratory distress syndrome (SARS). J Neuro 2004; 251:12271231.
  • 51
    Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009; 3:129142.
  • 52
    Radigan KA, Urich D, Misharin AV et al. The effect of rosuvastatin in a murine model of influenza A infection. PLoS ONE 2012; 7:e35788.
  • 53
    Kumaki Y, Morrey JD, Barnard DL. Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. Future Virol 2012; 7:801818.
  • 54
    Kwong JC, Li P, Redelmeier DA. Influenza morbidity and mortality in elderly patients receiving statins: a cohort study. PLoS ONE 2009; 4:e8087.
  • 55
    Brett SJ, Myles P, Lim WS et al. Influenza Clinical Information Network (FLU-CIN). Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS ONE 2011; 6:e18120.
  • 56
    Vandermeer ML, Thomas AR, Kamimoto L et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:1319.
  • 57
    Makris D, Manoulakas E, Komnos A et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011; 39:24402446.
  • 58
    Tahan F, Ozcan A, Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial. Eur Respir J 2007; 29:9197.
  • 59
    Yamaya M, Shinya K, Hatachi Y et al. Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells. J Pharmacol Exp Ther 2010; 333:8190.
  • 60
    Viasus D, Paño-Pardo JR, Cordero E et al. Effect of immunomodulatory therapies in patients with pandemic influenza A (H1N1) 2009 complicated by pneumonia. J Infect 2011; 62:193199.
  • 61
    Ishii H, Komiya K, Yamagata E et al. Clarithromycin has limited effects in non-elderly, non-severe patients with seasonal influenza virus A infection. J Infect 2012; 64:343345.
  • 62
    Martín-Loeches I, Bermejo-Martin JF, Vallés J et al. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 2013; 39:693702.
  • 63
    Ray WA, Murray KT, Hall K et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:18811890.
  • 64
    Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:29652968.
  • 65
    Bauer CM, Zavitz CC, Botelho FM et al. Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS ONE 2010; 5:e13251.
  • 66
    Aldridge JR Jr, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106:53065311.
  • 67
    Pitocco D, Giubilato S, Zaccardi F et al. Pioglitazone reduces monocyte activation in type 2 diabetes. Acta Diabetol 2009; 46:7577.
  • 68
    Moseley CE, Webster RG, Aldridge JR. Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice. Influenza Other Respi Viruses 2010; 4:307311.
  • 69
    Carey MA, Bradbury JA, Seubert JM et al. Contrasting effects of cyclooxygenase-1 (COX-1) and COX-2 deficiency on the host response to influenza A viral infection. J Immunol 2005; 175:68786884.
  • 70
    Carey MA, Bradbury JA, Rebolloso YD et al. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. PLoS ONE 2010; 5:e11610.
  • 71
    Lee SM, Gai WW, Cheung TK, Peiris JS. Antiviral effect of a selective COX-2 inhibitor on H5N1 infection in vitro. Antiviral Res 2011; 91:330334.
  • 72
    Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:80918096.